Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Angelo Maria Patti, Ali A. Rizvi, Rosaria Vincenza Giglio, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 4, pp. 912-912
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
Srikanth Krishnan, Pratyaksh K. Srivastava, Jayram Attaluri, et al.
Journal of Cardiovascular Development and Disease (2025) Vol. 12, Iss. 1, pp. 19-19
Open Access | Times Cited: 2
The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
Elena Massimino, Anna Izzo, Gabriele Riccardi, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 1958-1958
Open Access | Times Cited: 62
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al-Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 10
Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases
Rosaria Vincenza Giglio, Bruna Lo Sasso, Luisa Agnello, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 11, pp. 3634-3634
Open Access | Times Cited: 60
Activation of Glucagon‐Like Peptide‐1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism‐Independent Pathway
Qiang Li, Mengxiao Jia, Zhencheng Yan, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 14
Open Access | Times Cited: 52
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Rosaria Vincenza Giglio, Anca Pantea Stoian, Khalid Al‐Rasadi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4633-4633
Open Access | Times Cited: 42
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
Rosaria Vincenza Giglio, Angelo Maria Patti, Ali A. Rizvi, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 291-291
Open Access | Times Cited: 19
Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
Amy L. McKenzie, Shaminie J. Athinarayanan
Diabetes Therapy (2024) Vol. 15, Iss. 4, pp. 843-853
Open Access | Times Cited: 7
Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes
Zongyi Wu, Wei Deng, Yiming Ye, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Walter Masson, Martín Lobo, Juan Patricio Nogueira, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study
Angelo Maria Patti, Dragana Nikolić, Antonio Magán‐Fernández, et al.
Diabetes Research and Clinical Practice (2019) Vol. 149, pp. 163-169
Open Access | Times Cited: 50
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
Emilie H. Zobel, R Ripa, Bernt Johan von Scholten, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 37
Gastroprotective effect of dapagliflozin in ethanol-induced gastric lesions in rats: Crosstalk between HMGB1/RAGE/PTX3 and TLR4/MyD88/VEGF/PDGF signaling pathways
Rania M. Salama, Rodaina H Ahmed, Alaa A Farid, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109686-109686
Closed Access | Times Cited: 16
Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
Guillaume Mahé, Victor Aboyans, E. Cosson, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis
Teodor Salmen, Liviu Ionuț Șerbănoiu, Cristina Bică, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9760-9760
Open Access | Times Cited: 13
Impaired fasting glucose and sulfonylureas increased the risk of major cardiovascular events in patients with inflammatory arthritis
Huan Meng, Ho So, Steven Ho Man Lam, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials
Hazem Mohamed Salamah, Ahmed Marey, Mohamed Abugdida, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Sultan A. Alfawaz, Abdulhadi S. Burzangi, Ahmed Esmat
Cureus (2024)
Open Access | Times Cited: 3
From Sedentary to Success: How Physical Activity Transforms Diabetes Management: A Systematic Review
Sorina Ispas, Andreea Nelson Twakor, Nicoleta Mihaela Mindrescu, et al.
Journal of Mind and Medical Sciences (2025) Vol. 12, Iss. 1, pp. 10-10
Open Access
New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes
Angelo Maria Patti, Rosaria Vincenza Giglio, Marcello Ciaccio, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 664-664
Open Access
The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions
Toka Elemary, Mina Nicola, Mohamed E. A. Abdelrahim, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis
Rumina Hasan, Uliana Y. Chugaeva, Mahdi Mohammadian, et al.
PLoS ONE (2025) Vol. 20, Iss. 5, pp. e0321032-e0321032
Open Access
Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus
Rosaria Vincenza Giglio, Anca Pantea Stoian, Martin Haluzı́k, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1867, Iss. 8, pp. 166148-166148
Open Access | Times Cited: 22
An observational multi-center study on type 2 diabetes treatment prescribing pattern and patient adherence to treatment
Muhammad Daoud Butt, Siew Chin Ong, Azra Rafiq, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Comparative Analysis of Biomarkers in Type 2 Diabetes Patients With and Without Comorbidities: Insights Into the Role of Hypertension and Cardiovascular Disease
Symeon Savvopoulos, Haralampos Hatzikirou, Herbert F. Jelinek
Biomarker Insights (2024) Vol. 19
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top